Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. (Q42285404)
Jump to navigation
Jump to search
scientific article published on 9 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. |
scientific article published on 9 July 2013 |
Statements
1 reference
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. (English)
1 reference
J Windyga
1 reference
T Lissitchkov
1 reference
O Stasyshyn
1 reference
V Mamonov
1 reference
L Rusen
1 reference
J L Lamas
1 reference
M-S Oh
1 reference
M Chapman
1 reference
S Fritsch
1 reference
B G Pavlova
1 reference
W-Y Wong
1 reference
B E Abbuehl
1 reference
9 July 2013
1 reference
1 reference
20
1 reference
1
1 reference
15-24
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference